Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.55 |
| ▸ | FLT4 | P35916 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658372 | 0.86 | POLB (0.50) | POLBANO1APEX1NPC1RAB9A | |
| SCHEMBL6415937 | 0.84 | KDM4E (0.61) | FLT1FLT4KDRPOLBAPEX1 | |
| SCHEMBL2102110 | 0.83 | ANO1 (0.49) | FLT1FLT4KDRPOLBANO1 | |
| SCHEMBL4926140 | 0.82 | SMN1; SMN2 (0.51) | FLT1FLT4KDRPOLBAPEX1 | |
| SCHEMBL6415657 | 0.81 | POLB (0.61) | FLT1FLT4KDRPOLBANO1 | |
| SCHEMBL2335621 | 0.81 | FLT1 (0.54) | FLT1FLT4KDRPOLBANO1 | |
| SCHEMBL13152444 | 0.81 | ABL1 (0.58) | FLT1FLT4KDRPOLBANO1 | |
| SCHEMBL2102097 | 0.80 | ALDH1A1 (0.46) | ANO1KCNMA1MEN1KMT2A | |
| SCHEMBL8318320 | 0.80 | FLT1 (0.59) | FLT1FLT4KDRPOLBCYP11B2 | |
| SCHEMBL4599072 | 0.79 | POLB (0.50) | POLBANO1APEX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910274-B1 | PHENYL COMPOUNDS | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1910274-B1 | PHENYL COMPOUNDS | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| EP-1910274-A1 | PHENYL COMPOUNDS | Eli Lilly and Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015807-A1 | PHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015807-A1 | PHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | DPP4, GPR119, SLC5A2 | FLT1 4410/4885FLT4 3680/4885KDR 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.